HSP90AA1 and myeloproliferative neoplasm: However, the first clinical trial that attempted to inhibit HSP90 was a disappointment: patients developed serious adverse effects, and the relevance of HSP90 inhibition as a therapeutic strategy in MPN was called into question [52].